Over-expression of the other ErbB receptors in SCCHN has been reported (ErbB2, 3–29%; ErbB3, 21%; ErbB4, 26%), and can also contribute to disease progression [4]. Here, ERBB2 is linked to head and neck squamous cell carcinoma.